Hip Arthritis, Hip Arthropathy, Hip Dysplasia, Hip Fractures, Hip Necrosis, Hip Osteoarthritis
Conditions
Brief summary
EUROSSTEM is intended for use in primary and revision total hip replacement surgery. Hip replacement is intended to provide increased patient mobility and reduce pain by replacing the damages hip joint articulation in patients where there is evidence of sufficient sound bone to seat and support the components. As part of post market vigilance, EUROS will collect data on EUROSTEM performances and safety
Detailed description
Post market observational study. This study is multicenter, prospective, non comparative.
Interventions
DEVICEhip arthroplasty
Hip prosthesis surgery
Sponsors
EUROS
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient who received EUROSTEM * Patient informed of its participation to the study * Patient aged over 18 to date of surgery
Exclusion criteria
* Patient presenting a contraindication to EUROSTEM implantation. * Patient who refused to participate to the study * Vulnerable subjects
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety of EUROSTEM Femoral Stem | 1 year | Collect the safety of the device trought complications occurence rate |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Radiological performances of EUROSTEM Femoral Stem | 1 year | Collect the performances of the device trought radiological evaluation |
| Clinical performances of EUROSTEM Femoral Stem | 1 year | Collect the performances of the device trought clinical scores |
| Survival of EUROSTEM Femoral Stem | 10 year | Assess the survival rate of the device |
Countries
France
Outcome results
None listed